HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (pyridine- 3- ylmethyl)- 5- (7- hydroxy- 2,6,8- trimethyl- 1,2,4a,5,6,7,8,8a- octahydronaphthalene- 1- yl)- 2- methylpenta- 2,4- dienamide

an ADP-ribosylation factor 1 inactivator; has antineoplastic and angiogenesis inhibitory activity; structure in first source

Also Known As:

2-methylcoprophilinamide; AMF-26; M-COPA compound

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Eggenweiler, Hans-Michael: 1 article (01/2017)
2.	Gendarme, Mathieu: 1 article (01/2017)
3.	Ignashkova, Tatiana I: 1 article (01/2017)
4.	Lindemann, Ralph K: 1 article (01/2017)
5.	Peschk, Katrin: 1 article (01/2017)
6.	Reiling, Jan H: 1 article (01/2017)
7.	Fukunaga, Yuichi: 1 article (07/2012)
8.	Furuno, Ayana: 1 article (07/2012)
9.	Hosoi, Fumihito: 1 article (07/2012)
10.	Kawahara, Akihiko: 1 article (07/2012)

Related Diseases

1.	Neoplasms (Cancer) 07/15/2012 - "AMF-26 could be a promising novel candidate drug for cancer treatments." 01/01/2017 - "Using several human cancer cell lines, we studied the effects of AMF-26, BFA and golgicide A on cell homeostasis including Golgi structure, endoplasmic reticulum (ER) stress markers, secretion and viability, and found overall a significant correlation between these parameters. " 07/15/2012 - "We found that the TNF-α-induced phosphorylation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα) and nuclear translocation of p65 were impaired by AMF-26 in both endothelial cells and cancer cells. " 07/15/2012 - "Oral administration of AMF-26 significantly blocked VEGF- or IL-1β-induced angiogenesis in the mouse cornea, and also tumor angiogenesis and growth. " 02/03/2012 - "AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy."
2.	Breast Neoplasms (Breast Cancer) 02/03/2012 - "In addition, orally administrated AMF-26 (83 mg/kg of body weight; 5 days) induced complete regression of human breast cancer BSY-1 xenografts in vivo, suggesting that AMF-26 is a novel anticancer drug candidate that inhibits the Golgi system, targeting Arf1 activation."
3.	Body Weight (Weight, Body) 02/03/2012 - "In addition, orally administrated AMF-26 (83 mg/kg of body weight; 5 days) induced complete regression of human breast cancer BSY-1 xenografts in vivo, suggesting that AMF-26 is a novel anticancer drug candidate that inhibits the Golgi system, targeting Arf1 activation."

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	ADP-Ribosylation Factor 1
3.	Peptides (Polypeptides)
4.	golgicide A

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration